Narbone M C, Abbate M, Gangemi S
A.O.U. G. Martino, Clinica Neurologica I, Via C. Valeria, Contesse, I-98124 Messina, Italy.
Neurol Sci. 2004 Oct;25 Suppl 3:S113-8. doi: 10.1007/s10072-004-0266-8.
The availability of an effective drug for attack treatment is a main need of migraine patients. Symptomatic therapy of migraine now includes three main classes of drugs: ergot alkaloids, nonsteroidal antiinflammatory drugs (NSAIDs) and triptans. Clinical randomised placebo-controlled trials affirmed the efficacy and tolerability of these drugs, when used at the recommended doses and in the absence of contraindications. The efficacy data from comparative trials showed a trend in favour of triptans vs. ergot alkaloids, but failed to show significant differences between triptans and NSAIDs. However, clinical practice experience of most headache clinicians suggests that triptans provide superior efficacy in comparison with nonspecific agents, mainly in that they better satisfy migraine patient expectations. In fact, these selective specific antimigraine drugs are an advance in acute migraine treatment.
对于偏头痛患者来说，能获得一种有效的发作期治疗药物是主要需求。目前偏头痛的症状性治疗包括三大类药物：麦角生物碱、非甾体抗炎药（NSAIDs）和曲坦类药物。临床随机安慰剂对照试验证实了这些药物在推荐剂量使用且无禁忌证时的疗效和耐受性。比较试验的疗效数据显示，与麦角生物碱相比，曲坦类药物有一定优势，但曲坦类药物与非甾体抗炎药之间未显示出显著差异。然而，大多数头痛临床医生的临床实践经验表明，与非特异性药物相比，曲坦类药物疗效更佳，主要体现在它们能更好地满足偏头痛患者的期望。事实上，这些选择性特异性抗偏头痛药物是急性偏头痛治疗的一大进步。
